First Clinical Data from Combination of X4P-001- IO and Keytruda® (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced that the first data from its ongoing Phase 1b clinical study of X4P-001-IO in patients with melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 8-12 in National Harbor, MD. A second poster highlighting the effects of CXCR4 inhibition in a syngeneic model of melanoma will also be presented.

This entry was posted in Recent Development News: Q4 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »